MA52165A - Inhibiteurs sélectifs de l'isoforme tgfbeta1 et utilisation associée - Google Patents

Inhibiteurs sélectifs de l'isoforme tgfbeta1 et utilisation associée

Info

Publication number
MA52165A
MA52165A MA052165A MA52165A MA52165A MA 52165 A MA52165 A MA 52165A MA 052165 A MA052165 A MA 052165A MA 52165 A MA52165 A MA 52165A MA 52165 A MA52165 A MA 52165A
Authority
MA
Morocco
Prior art keywords
tgfbeta1
selective
associated use
isoform inhibitors
isoform
Prior art date
Application number
MA052165A
Other languages
English (en)
Inventor
Andrew Avery
Alan Buckler
Allan Capili
Gregory J Carven
Christopher Chapron
Anthony Cooper
Kevin B Dagbay
Abhishek Datta
Justin W Jackson
Susan Lin
Christopher Littlefield
Constance Martin
Matthew Salotto
Thomas Schurpf
Caitlin Stein
Stefan Wawersik
Original Assignee
Scholar Rock Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scholar Rock Inc filed Critical Scholar Rock Inc
Publication of MA52165A publication Critical patent/MA52165A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
MA052165A 2018-07-11 2019-07-11 Inhibiteurs sélectifs de l'isoforme tgfbeta1 et utilisation associée MA52165A (fr)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201862696752P 2018-07-11 2018-07-11
US201862696774P 2018-07-11 2018-07-11
US201862718196P 2018-08-13 2018-08-13
US201862722081P 2018-08-23 2018-08-23
US201862737534P 2018-09-27 2018-09-27
US201862758180P 2018-11-09 2018-11-09
US201862757917P 2018-11-09 2018-11-09
US201962810263P 2019-02-25 2019-02-25
US201962827552P 2019-04-01 2019-04-01

Publications (1)

Publication Number Publication Date
MA52165A true MA52165A (fr) 2021-06-02

Family

ID=67437706

Family Applications (1)

Application Number Title Priority Date Filing Date
MA052165A MA52165A (fr) 2018-07-11 2019-07-11 Inhibiteurs sélectifs de l'isoforme tgfbeta1 et utilisation associée

Country Status (13)

Country Link
US (2) US11130803B2 (fr)
EP (2) EP3677278B1 (fr)
CY (1) CY1125076T1 (fr)
DK (1) DK3677278T3 (fr)
ES (1) ES2905160T3 (fr)
HR (1) HRP20212034T1 (fr)
HU (1) HUE056501T2 (fr)
LT (1) LT3677278T (fr)
MA (1) MA52165A (fr)
PL (1) PL3677278T3 (fr)
PT (1) PT3677278T (fr)
RS (1) RS62914B1 (fr)
SI (1) SI3677278T1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117510630A (zh) * 2020-03-19 2024-02-06 基因泰克公司 同种型选择性抗TGF-β抗体及使用方法
CN114645042A (zh) * 2020-12-18 2022-06-21 中国食品药品检定研究院 一种构建具有表达荧光素酶和红色荧光蛋白的重组巨噬细胞的转基因小鼠的方法
WO2022256723A2 (fr) * 2021-06-03 2022-12-08 Scholar Rock, Inc. Inhibiteurs de tgf-bêta et leur utilisation thérapeutique
TW202334209A (zh) * 2021-11-01 2023-09-01 美商健臻公司 成骨不全症之治療
CN114236137A (zh) * 2021-12-17 2022-03-25 中山大学·深圳 一种转化生长因子β的体外检测试剂盒及其应用

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (fr) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Récepteurs chimériques par liaison et expression de l'ADN
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
EP0436597B1 (fr) 1988-09-02 1997-04-02 Protein Engineering Corporation Production et selection de proteines de liaison diversifiees de recombinaison
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
EP0585287B1 (fr) 1990-07-10 1999-10-13 Cambridge Antibody Technology Limited Methode de production de chainons de paires de liaison specifique
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
EP0564531B1 (fr) 1990-12-03 1998-03-25 Genentech, Inc. Methode d'enrichissement pour des variantes de l'hormone de croissance avec des proprietes de liaison modifiees
AU1545692A (en) 1991-03-01 1992-10-06 Protein Engineering Corporation Process for the development of binding mini-proteins
JP3672306B2 (ja) 1991-04-10 2005-07-20 ザ スクリップス リサーチ インスティテュート ファージミドを使用するヘテロ二量体受容体ライブラリー
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
AU729406B2 (en) 1996-03-28 2001-02-01 Johns Hopkins University, The Soluble divalent and multivalent heterodimeric analogs of proteins
US6114148C1 (en) 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
US6492497B1 (en) 1999-04-30 2002-12-10 Cambridge Antibody Technology Limited Specific binding members for TGFbeta1
EP2386575A3 (fr) 2000-06-29 2011-11-30 Abbott Laboratories Anticorps à double spécificité et leurs procédés de fabrication et d'utilisation
US7803553B2 (en) 2003-09-04 2010-09-28 Riken Methods of use of antibodies which recognize a protease cleavage site of an LAP fragment of TGF-β
TR201901929T4 (tr) 2005-02-08 2019-03-21 Genzyme Corp TGFBeta'ya antikorlar.
PE20091163A1 (es) 2007-11-01 2009-08-09 Wyeth Corp Anticuerpos para gdf8
US20100260668A1 (en) 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
MX2010013236A (es) 2008-06-03 2011-02-24 Abbott Lab Inmunoglobulinas de dominio variable doble y usos de las mismas.
AR081556A1 (es) 2010-06-03 2012-10-03 Glaxo Group Ltd Proteinas de union al antigeno humanizadas
SI2780368T1 (en) 2011-11-14 2018-04-30 Regeneron Pharmaceuticals, Inc. INGREDIENTS AND PROCEDURES FOR INCREASING PURE MASS AND MICROWAVE WITH SPECIFIC ANTAGONISING OF GDF8 AND / OR ACTIVITY A
CA2890733A1 (fr) 2012-11-06 2014-05-15 Scholar Rock, Inc. Compositions et procedes pour la modulation de la signalisation cellulaire
EP2981822B1 (fr) 2013-05-06 2020-09-02 Scholar Rock, Inc. Compositions et procédés de modulation du facteur de croissance
US20170073406A1 (en) 2014-05-06 2017-03-16 Scholar Rock, Inc. Compositions and methods for growth factor modulation
WO2016073853A1 (fr) 2014-11-06 2016-05-12 Scholar Rock, Inc. Anticorps anti-pro-myostatine/myostatine latente et leurs utilisations
EP3307772B1 (fr) 2015-06-12 2020-09-09 Ludwig Institute For Cancer Research Limited Anticorps spécifiques de tgf-bêta 3 et procédés et utilisations associés
AU2016297248A1 (en) 2015-07-22 2018-02-15 Scholar Rock, Inc. GDF11 binding proteins and uses thereof
MX2018003196A (es) 2015-09-15 2019-05-16 Scholar Rock Inc Anticuerpos anti-promiostatina o miostatina latente y usos de los mismos.
HUE062976T2 (hu) 2016-03-11 2023-12-28 Scholar Rock Inc TGFbéta1-hez kötõdõ immunglobulinok és alkalmazásuk
KR102577551B1 (ko) 2016-07-14 2023-09-11 스칼러 락, 인크. TGFβ 항체, 방법 및 용도
WO2018129329A1 (fr) 2017-01-06 2018-07-12 Scholar Rock, Inc. INHIBITEURS SPÉCIFIQUES D'UNE ISOFORME, PERMISSIFS AU CONTEXTE DE TGFβ1 ET LEUR UTILISATION
WO2019023661A1 (fr) 2017-07-28 2019-01-31 Scholar Rock, Inc. Inhibiteurs spécifiques du complexe ltbp de tgf-bêta 1 et leurs utilisations
WO2020014460A1 (fr) 2018-07-11 2020-01-16 Scholar Rock, Inc. INHIBITEURS DE TGFβ1 SÉLECTIFS SELON L'ISOFORME À AFFINITÉ ÉLEVÉE
TW202019957A (zh) 2018-07-11 2020-06-01 美商供石公司 TGFβ1抑制劑及其用途

Also Published As

Publication number Publication date
CY1125076T1 (el) 2023-06-09
HRP20212034T1 (hr) 2022-04-01
PT3677278T (pt) 2022-02-03
PL3677278T3 (pl) 2022-02-28
ES2905160T3 (es) 2022-04-07
DK3677278T3 (da) 2022-01-10
EP4019046A1 (fr) 2022-06-29
US20220064275A1 (en) 2022-03-03
LT3677278T (lt) 2022-01-10
EP3677278B1 (fr) 2021-11-10
HUE056501T2 (hu) 2022-02-28
US20200079840A1 (en) 2020-03-12
SI3677278T1 (sl) 2022-01-31
RS62914B1 (sr) 2022-03-31
EP3677278A1 (fr) 2020-07-08
US11130803B2 (en) 2021-09-28

Similar Documents

Publication Publication Date Title
MA52165A (fr) Inhibiteurs sélectifs de l'isoforme tgfbeta1 et utilisation associée
MA50077A (fr) Inhibiteurs de kras g12c et leurs procédés d'utilisation
MA48772A (fr) Inhibiteurs de kras g12c et leurs procédés d'utilisation
MA51848A (fr) Inhibiteurs de kras g12c et leurs procédés d'utilisation
MA52501A (fr) Inhibiteurs de kras g12c et leurs procédés d'utilisation
MA52765A (fr) Inhibiteurs de kras g12c et leurs procédés d'utilisation
MA52496A (fr) Inhibiteurs de kras g12c et leurs procédés d'utilisation
IL267790A (en) Isoform-specific, context-permissive tgfbeta1 inhibitors and their use
MA49950A (fr) Anticorps anti-b7-h4 et leurs procédés d'utilisation
MA51616A (fr) Inhibiteurs d'adn-pk
MA52004A (fr) Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glycopyranosidase
MA52963A (fr) Inhibiteurs de protéine tyrosine phosphatase et leurs procédés d'utilisation
MA52284A (fr) Anticorps anti-hla-g et leur utilisation
MA51837A (fr) Inhibiteurs de l'arginase et leurs procédés d'utilisation
MA50912A (fr) Inhibiteurs d'acss2 et leurs procédés d'utilisation
MA53235A (fr) Indoles substitués et procédés d'utilisation associés
MA52797A (fr) Inhibiteurs de masp -2 et procédés d'utilisation
MA54261A (fr) Inhibiteurs de pcsk9 et leurs procédés d'utilisation
MA50038A (fr) Anticorps anti-pd-l1 de et son utilisation
MA53015A (fr) Anticorps anti-sirp-bêta1 et procédés d'utilisation associés
SG11202104010PA (en) Rgmc-selective inhibitors and use thereof
MA54758A (fr) Inhibiteurs de pcsk9 et leurs procédés d'utilisation
MA48793A (fr) Procédés de fabrication et d'utilisation d'inhibiteurs de pde9
ZA202102192B (en) Fgfr4 inhibitor and use thereof
MA50516A (fr) Anticorps anti-apoc3 et leurs procédés d'utilisation